

REMARKS

Restriction is required under 35 U.S.C. 121 and 372. Applicants hereby elect Group I with traverse. Applicants believe that Group VI should be joined with Group I. Group I, claims 7-11, is drawn to a crystal of *H. pylori* Muri complexed with an inhibitor. Group VI, claims 2-4, is drawn to a crystal of *H. pylori* Muri complexed with an inhibitor and a substrate. The class and subclass of both Group I and Group VI are the same and Applicants believe that searching for the substrate, extra element of claim 2, would not place an undue burden of work on the Examiner as a search of the crystal and the inhibitor would likely reveal also the presence of the substrate. Therefore, Applicants respectfully request the joinder of Group I and VI.


By way of this amendment, claims 3, 4, 7, 12-27 and 41-47 have been cancelled and claims 2 and 28-40 have been withdrawn. Claim 1 has been amended to incorporate the limitation of claim 7 and claims 8-11 have been amended to correct dependencies.

Upon entry of this amendment claims 1, 5-6 and 8-11 will be pending. Applicants reserve the right to prosecute the claims of the non-elected Groups.

Conclusion

Applicants respectfully submit that claims 1, 5-6 and 8-11 are in condition for allowance, which action is respectfully requested. Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100966.

Respectfully submitted,



Name: Christine McCormack
Dated: January 27, 2006
Reg. No.: L0065
Phone No.: 1 781 839 4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451